MedTrace Logo

Synaptic Imaging and Network Activity in Treatment Resistant Depression

NCT05870501 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 56

Last updated 2024-11-18

No results posted yet for this study

Summary

The main aim of this research is to explore the effects that ketamine has on the functional connectivity of the brain in participants with treatment resistant depression (TRD). This study will investigate the relationship between these changes and response to treatment as measured by clinical scales, as well as examining drug induced changes in reward and emotion based brain activity, structural connectivity, cerebral blood flow, cognition, metabolism and blood markers of brain plasticity.

Conditions

  • Depressive Disorder
  • Depressive Disorder, Major
  • Depressive Disorder, Treatment-Resistant
  • Bipolar Disorder
  • Bipolar Disorder I
  • Bipolar Disorder II
  • Mood Disorders
  • Anhedonia

Interventions

DRUG

Ketamine

0.5mg/kg IV infusion

DRUG

Midazolam

0.045mg/kg IV infusion

Sponsors & Collaborators

Principal Investigators

  • Mitul Mehta, PhD · King's College London

Study Design

Allocation
RANDOMIZED
Purpose
BASIC_SCIENCE
Masking
QUADRUPLE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
55 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-10-20
Primary Completion
2023-09-13
Completion
2023-09-13

Countries

  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05870501 on ClinicalTrials.gov